Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Broussonetia papyrifera* extract, derived from the paper mulberry tree, is a botanical extract investigated for its anti-inflammatory, skin barrier-improving, and reproductive inhibitory properties. In dermatological research, specific fractions of the extract have been shown to inhibit inflammatory markers such as monocyte chemoattractant protein-1 (MCP-1) and CD86, while suppressing chemokine signaling pathways. Additionally, an alkaloid-rich fraction has been identified to activate the PPAR signaling pathway, promoting ceramide production and improving skin barrier function. Beyond skin health, the extract is being explored as a plant-based sterility agent for rodent population control, where it has demonstrated the ability to inhibit sex organ growth and reduce testosterone levels and sperm quality in male rodents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on broussonetia papyrifera extract.